Targeted Drug Inhibitors Mk-1775 CAS 955365-80-7 for Treat Ovarian Cancer - Product
Place of Origin : Wuhan,China
Delivery Terms : FOB
Delivery Time : Ready Goods Within One Week
Product Capacity : 1000kg/month
Payment Terms : L/C
Product Description
Model NO.: 955365-80-7
Suitable for: Adult
Purity: >99%
Product Name: Mk-1775
Delivery: Safe & Timely, Around 7days After Payment.
Specification: 1kg foil bag or as require
Powder: Yes
State: Solid
Assay: 99%
Description: Yellow Powder
Alias: Mk1775
Transport Package: Discreet Package for Delivery Guarantee
COA
Product Name MK-1775
CAS 955365-80-7
MF C27H32N8O2
MW 500.59538
Appearance yellow powder
Package 50G/foil bag
Standard enterprise standard
Assay 99%
Grade medical grade
Basic Information
Brand : Besteroids
Material : Powder
Color : Yellow
Physical Specification
Size or Volume : 25kg
Other Specification : MK-1775 Description:
MK-1775 Is A Small Molecule Inhibitor Of The Tyrosine Kinase WEE1 With Potential Antineoplastic Sensitizing Activity. MK-1775 Selectively Targets And Inhibits WEE1, A Tyrosine Kinase That Phosphorylates Cyclin-dependent Kinase 1 (CDK1, CDC2) To Inactivate The CDC2/cyclin B Complex. Inhibition Of WEE1 Activity Prevents The Phosphorylation Of CDC2 And Impairs The G2 DNA Damage Checkpoint. This May Lead To Apoptosis Upon Treatment With DNA Damaging Chemotherapeutic Agents. MK-1775 Is A Type Of Biological Therapy. It Is A Cancer Growth Blocker. It Stops Signals That Cancer Cells Use To Divide And Grow. MK-1775 Has Been Used In Trials Studying The Treatment Of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, And Adult Glioblastoma, Among Others.
MK-1775 Applicaiton:
MK-1775 Inhibits Wee1 Kinase In An ATP-competitive Manner. Compared To Wee1, MK-1775 Displays 2- To 3-fold Less Potency Against Yes With IC50 Of 14 NM, 10-fold Less Potency Against Seven Other Kinases With >80% Inhibition At 1 μM, And >100-fold Selectivity Over Human Myt 1, Another Kinase That Inhibits Cyclin-dependent Kinase 1 (CDC2) By Phosphorylation At An Alternative Site (Thr14). By Abrogating The DNA Damage Checkpoint Via Blockade Of Wee1 Activity In WiDr Cells Bearing Mutated P53, MK-1775 Treatment Inhibits The Basal Phosphorylation Of CDC2 At Tyr15 (CDC2Y15) With EC50 Of 49 NM, And Suppresses Gemcitabine-, Carboplatin- Or Cisplatin-induced Phosphorylation Of CDC2 And Cell Cycle Arrest In A Dose-dependent Manner, With EC50 Of 82 NM And 81 NM, 180 NM And 163 NM, As Well As 159 NM And 160 NM, Respectively. MK-1775 Treatment Alone At 30-100 NM Has No Significant Antiproliferative Effect In WiDr And H1299 Cells, Whereas MK-1775 At 300 NM, Sufficient To Inhibit Wee1 By >80%, Displays Moderate But Significant Antiproliferative Effects By 34.1% In WiDr Cells And 28.4% In H1299 Cells.
